|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-2-21
|
|
pubmed:abstractText |
High dose myeloablative chemotherapy ("megatherapy"), with haematopoietic stem cell support, is now widely used to consolidate response to induction chemotherapy in patients with advanced neuroblastoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1545-5009
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
348-57
|
|
pubmed:dateRevised |
2009-1-12
|
|
pubmed:meshHeading |
pubmed-meshheading:15546135-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15546135-Child, Preschool,
pubmed-meshheading:15546135-Combined Modality Therapy,
pubmed-meshheading:15546135-Disease-Free Survival,
pubmed-meshheading:15546135-Europe,
pubmed-meshheading:15546135-Female,
pubmed-meshheading:15546135-Humans,
pubmed-meshheading:15546135-Infant,
pubmed-meshheading:15546135-Life Tables,
pubmed-meshheading:15546135-Male,
pubmed-meshheading:15546135-Melphalan,
pubmed-meshheading:15546135-Neuroblastoma,
pubmed-meshheading:15546135-Survival Rate
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
|
|
pubmed:affiliation |
Department of Surgery, Institute of Child Health, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
